Found 1 Presentation For Request "382P"
382P - Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study
- Manuel Valladares (Cordoba, Spain)
Abstract
Background
Solid biopsy (SB) is commonly used to assess
Methods
Prospective, observational, multi-centre study in
Results
In pt under P+CT, % of Proportions of mutated patients based on the number of samples analysed at each time point. ∗ Discordant patients between solid biopsy and circulating free DNA.
Patients treated with panitumumab (n= 103) Baseline (n=103) 20 ± 2 weeks (n=74) Disease progression (n=45) 7 (6.8%)* 2 (2.7%) 7 (15.6%) 5 (4.9%) 2 (2.7%) 5 (11.1%) 2 (1.9%) 0 (0%) 2 (4.5%)
Conclusions
The highest proportion of
Clinical trial identification
NCT02792478, April 2015.
Editorial acknowledgement
The authors wish to thank Irene Mansilla-Núñez from TFS HealthScience for the medical writing support.
Legal entity responsible for the study
Amgen S.A.
Funding
Amgen S.A.
Disclosure
M. Valladares: Financial Interests, Other: Roche, Merck, Amgen, Sanofi, Servier, Bayer, Celgene. M.J. Safont Aguileria: Financial Interests, Advisory Role, and funding to attend congresses and training.: Roche, Merck, Amgen, Sanofi; Financial Interests, Advisory Role: Servier, Bayer, MSD, BMS, Pierre Fabre. E. González-Flores: Financial Interests, Advisory Board, and lectures: Amgen. P. García Alfonso: Financial Interests, Advisory Role, and speaker: Amgen, Merck, Bristol, Sanofi, Servier, Bayer, MSD, Lilly, Pierre Fabre, Roche. E. Aranda Aguilar: Financial Interests, Advisory Role: Amgen, Merck, Bristol Myers Squibb, Sanofi, Bayer, Roche. M. Llanos-Munoz: Financial Interests, Invited Speaker, and advisory board.: Amgen, Roche; Financial Interests, Invited Speaker: AAA, Servier, Sanofi, Ipsen, Pierre Fabre; Financial Interests, Advisory Board: Incyte. J. Aparicio: Financial Interests, Advisory Role: Amgen, Merck, Sanofi, Servier, Bayer, Pierre Fabre. M. Salgado Fernandez: Financial Interests, Advisory Role, and speaker: Amgen. R. Vidal Tocino: Financial Interests, Advisory Role, and educational and scientific activities and travel support: Amgen, Sanofi, Roche, BMS; Financial Interests, Advisory Role: Merck, Servier, Bayer; Financial Interests, Other: educational and scientific activities and travel support: Pierre Fabre, Lilly. B. Massuti Sureda: Financial Interests, Speaker’s Bureau, Travel, Accommodations, Expenses and Advisory role: Roche; Financial Interests, Advisory Role, and Travel, Accommodations, Expenses: Merck Sharp & Dohme, Boehringer Ingelheim, Janssen; Financial Interests, Advisory Role: Bristol-Myers Squibb; Financial Interests, Speaker’s Bureau: AstraZeneca, Pfizer, Merck Serono, Amgen. R. Garcia-Carbonero: Financial Interests, Personal, Advisory Board: AAA, Advanz Pharma, Amgen, Bayer, HMP, Ipsen, Merck, Midatech, MSD, Novartis, Pierre Fabre, Roche, Servier; Financial Interests, Institutional, Research Grant: BMS, MSD, Pfizer; Non-Financial Interests, Leadership Role, Global PI of investigator-initiated clinical trials (AXINET, NICENEC, PEMBROLA): BMS, MSD, Pfizer; Other, Other, Honoraria received by spouse for advisory board or invited speaker roles: AbbVie, AstraZeneca, Bayer, Boehringer, Bms, Genomica, Lilly, MSD, Merck, Novartis, Pfizer, Pharma Mar, Roche, Sanofi, Servier, Takeda. A. Lloansi Vila: Financial Interests, Full or part-time Employment, and stakeholder: Amgen. All other authors have declared no conflicts of interest.